Clinical uses of cannabis and Catha edulis products
Loading...
Date
2024-01-01
Journal Title
Journal ISSN
Volume Title
Type
Article
Publisher
Elsevier
Series Info
Cannabis and Khat in Drug Discovery: the Discovery Pipeline and the Endocannabinoid System ; Pages 595 - 6281 January 2024
Scientific Journal Rankings
Abstract
The medicinal use of cannabis (Cannabis sativa) and khat (Catha edulis) as well as their products has been increased in the last decade. Medical cannabis and khat have been legalized in several countries. Additionally, the major cannabinoids, particularly cannabidiol and tetrahydrocannabinol, have been utilized for the development of FDA-approved pharmaceuticals. The clinical applications of cannabis and C. edulis products are complicated by legislation and regulations that are varied among countries. In this chapter, the pharmacological and the side effect profiles for the clinical uses of cannabis and C. edulis products are highlighted. Although, the clinical data for their use are continuing to evolve, the legal status needs to be authorized to keep the balance between clinical applications and limitations.
Description
Keywords
cannabis, cardiovascular disease, cellular process, clinical history finding, clinical trials side effects, cognitive process, cognitive psychology, drug, drug development, Khat, legal use, medicine, mental disorder, nervous system, nervous system disorder, neuroscience, organic compound, pain, pharmaceutical therapy, pharmacological parameter, pharmacology, pharmacology discipline, psychological disorders, therapeutic procedure, toxicity
Citation
Ezzat, S. M., Baki, P. M. A., Ibrahim, R. M., Elezz, D. A., Abdelaziz, M., & Salem, M. A. (2024). Clinical uses of cannabis and Catha edulis products. In Elsevier eBooks (pp. 595–628). https://doi.org/10.1016/b978-0-323-95927-8.00028-1